196 related articles for article (PubMed ID: 22087801)
1. Expert Delphi survey on research and development into drugs for neglected diseases.
Fehr A; Thürmann P; Razum O
BMC Health Serv Res; 2011 Nov; 11():312. PubMed ID: 22087801
[TBL] [Abstract][Full Text] [Related]
2. Evaluating and improving orphan drug regulations in Europe: a Delphi policy study.
Picavet E; Cassiman D; Simoens S
Health Policy; 2012 Nov; 108(1):1-9. PubMed ID: 22989856
[TBL] [Abstract][Full Text] [Related]
3. Orphan drug legislation: lessons for neglected tropical diseases.
Villa S; Compagni A; Reich MR
Int J Health Plann Manage; 2009; 24(1):27-42. PubMed ID: 18435430
[TBL] [Abstract][Full Text] [Related]
4. The role of academic institutions in the development of drugs for rare and neglected diseases.
Coles LD; Cloyd JC
Clin Pharmacol Ther; 2012 Aug; 92(2):193-202. PubMed ID: 22760003
[TBL] [Abstract][Full Text] [Related]
5. The roles of patents and research and development incentives in biopharmaceutical innovation.
Grabowski HG; DiMasi JA; Long G
Health Aff (Millwood); 2015 Feb; 34(2):302-10. PubMed ID: 25646111
[TBL] [Abstract][Full Text] [Related]
6. The view of experts on initiatives to be undertaken to promote equity in the access to orphan drugs and specialised care for rare diseases in Spain: A Delphi consensus.
Torrent-Farnell J; Comellas M; Poveda JL; Abaitua I; Gutiérrez-Solana LG; Pérez-López J; Cruz J; Urcelay J; Lizán L
Health Policy; 2018 Jun; 122(6):590-598. PubMed ID: 29572017
[TBL] [Abstract][Full Text] [Related]
7. The German government's global health strategy--a strategy also to support research and development for neglected diseases?
Fehr A; Razum O
Glob Health Action; 2014; 7():24565. PubMed ID: 25079287
[TBL] [Abstract][Full Text] [Related]
8. Analysis of Incentive Policies and Initiatives on Orphan Drug Development in China: Challenges, Reforms and Implications.
Zhao Z; Pei Z; Hu A; Zhang Y; Chen J
Orphanet J Rare Dis; 2023 Jul; 18(1):220. PubMed ID: 37501126
[TBL] [Abstract][Full Text] [Related]
9. Innovation and access to medicines for neglected populations: could a treaty address a broken pharmaceutical R&D system?
Moon S; Bermudez J; 't Hoen E
PLoS Med; 2012; 9(5):e1001218. PubMed ID: 22615544
[TBL] [Abstract][Full Text] [Related]
10. Is orphan drug status beneficial to tropical disease control? Comparison of the American and future European orphan drug acts.
Trouiller P; Battistella C; Pinel J; Pecoul B
Trop Med Int Health; 1999 Jun; 4(6):412-20. PubMed ID: 10444316
[TBL] [Abstract][Full Text] [Related]
11. Preserving an Incentive for Global Health R&D: The Priority Review Voucher Secondary Market.
Robertson AS
Am J Law Med; 2016 May; 42(2-3):524-542. PubMed ID: 29086641
[TBL] [Abstract][Full Text] [Related]
12. [Drugs for rare diseases: the blessing of being orphans.].
Costa E; Schieppati A; Luzzatto L; Remuzzi G
Recenti Prog Med; 2019 May; 110(5):221-229. PubMed ID: 31140454
[TBL] [Abstract][Full Text] [Related]
13. Fostering innovative product development for neglected tropical diseases through partnerships.
Starr A; Graef KM; Dent J
Pharm Pat Anal; 2016 Sep; 5(6):391-400. PubMed ID: 27813447
[TBL] [Abstract][Full Text] [Related]
14. Neglected tropical diseases in Europe: rare diseases and orphan drugs?
Calleri G; Angheben A; Albonico M
Infection; 2019 Feb; 47(1):3-5. PubMed ID: 30390200
[TBL] [Abstract][Full Text] [Related]
15. Evolution and current status of the Orphan Drug Act.
Asbury CH
Int J Technol Assess Health Care; 1992; 8(4):573-82. PubMed ID: 1464479
[TBL] [Abstract][Full Text] [Related]
16. Orphan Medicines for Pediatric Use: A Focus on the European Union.
Bolislis WR; Corriol-Rohou S; Hill-Venning C; Hoogland H; Joos A; King D; Kitcatt V; Le Visage G; Kühler TC
Clin Ther; 2019 Dec; 41(12):2630-2642. PubMed ID: 31704041
[TBL] [Abstract][Full Text] [Related]
17. [Authorization and reimbursement of orphan drugs in an international comparison].
Roll K; Stargardt T; Schreyögg J
Gesundheitswesen; 2011 Aug; 73(8-9):504-14. PubMed ID: 20848380
[TBL] [Abstract][Full Text] [Related]
18. International consensus: ovarian tissue cryopreservation in young Turner syndrome patients: outcomes of an ethical Delphi study including 55 experts from 16 different countries.
Schleedoorn MJ; Mulder BH; Braat DDM; Beerendonk CCM; Peek R; Nelen WLDM; Van Leeuwen E; Van der Velden AAEM; Fleischer K; Turner Fertility Expert Panel OBOT
Hum Reprod; 2020 May; 35(5):1061-1072. PubMed ID: 32348471
[TBL] [Abstract][Full Text] [Related]
19. Ask the experts.
Pecoul B; Pollastri M; McKerrow J; Bueno-Calderon JM
Future Med Chem; 2012 Jul; 4(11):1383-9. PubMed ID: 22857528
[TBL] [Abstract][Full Text] [Related]
20. Assessing 15 proposals for promoting innovation and access to medicines globally.
Hoffman SJ; So K;
Ann Glob Health; 2014; 80(6):432-43. PubMed ID: 25960092
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
